Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
325
resultados
Última actualización
12/09/2026 [07:30:00]
Resultados 250 a 275 de 325
Resumen de: US20260210962A1
0000 Disclosed herein are methods for detecting and treating viral infections. Disclosed is a method of detecting a virus, comprising obtaining a biological sample; capturing a plurality of membranous particles from the biological sample; measuring antigens and nucleic acid levels in the membranous particles or single virions from the biological sample; and measuring an amount of a viral RNA; wherein a virus is detected when the viral protein level or the amount of viral RNA is increased in comparison to a control sample.
Resumen de: US20260210948A1
0000 A method of identifying a ligand, which is a ligand for a target protein of interest, and which interacts with a homologous to E6AP C-terminus (HECT)-type E3 ligase; a composition comprising (a) a fluorescently labeled peptide comprising a PPxY motif, an E1 ubiquitin (Ub)-activating enzyme, an E2 Ub-conjugating enzyme, a HECT-type E3 ligase, Ub, adenosine triphosphate (ATP), and a reaction buffer or (b) a fluorescently labeled peptide comprising a PPxY motif, a Ub-charged E2 Ub-conjugating enzyme, a HECT-type E3 ligase, ATP, and a reaction buffer; and a composition comprising a ligand identified in accordance with the above method or a pharmaceutically acceptable salt thereof.
Resumen de: US20260212981A1
0000 Provided is a computer-implemented method for predicting a pharmacokinetic feature for a drug administered to a subject, such as maximum concentration or time to maximum concentration. The method includes: contacting a fluid of the subject with an electrochemical aptamer-based sensor capable of detecting the drug, receiving a series of output values of the electrochemical aptamer-based sensor over a period of time, and using the series of output values to predict the pharmacokinetic feature.
Resumen de: US20260209296A1
Tau reporter compositions, tau reporter cells, and tau reporter animals are provided that comprise a four-repeat (4R) tau isoform linked to a first reporter protein and a three-repeat (3R) tau isoform linked to a second reporter protein that is different from the first reporter protein. Methods are provided for making such tau reporter cells and tau reporter animals and for using such tau reporter cells and tau reporter animals for assessing the activity of tau-targeting reagents.
Resumen de: US20260210981A1
Disclosed herein are antibodies or antigen-binding fragments thereof and compositions comprising the same. Also disclosed are methods of detecting TAR DNA-binding protein 43 (TDP-43) in a biological sample, diagnosing a neurodegenerative disease in a subject, and selecting whether to enroll a subject in a clinical trial for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) using the antibodies or antigen-binding fragments thereof described herein. In addition, disclosed herein are immunoassay kits for selectively detecting TDP-43 in a biological sample.
Resumen de: US20260209322A1
0000 The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.
Resumen de: US20260210980A1
The present invention relates to a splice variant of an ICA1 protein that acts as a biomarker for a TDP-43 pathology. In particular, the present invention relates to methods for identifying a splice variant of ICA1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject.
Resumen de: US20260210903A1
0000 An organic electrolyte-gated field effect transistor biosensor contains a microfluidic channel structure formed from a dielectric thermoplastic material. A biorecognition entity immobilized within the microfluidic channel allows the biosensor to detect the presence or concentration of an analyte in an electrolyte fluid placed within the channel. The dielectric material separates the microfluidic channel from the gate electrode and from the semiconductor material connecting the drain and source electrodes, and protects the gate electrode and the semiconductor material from direct contact with the electrolyte fluid in the microfluidic channel, to provide the biosensor with a high capacitance. Methods of fabricating the biosensor by monolithic 3D printing are also provided.
Resumen de: WO2026156364A1
Provided herein is the identification of target proteins for determination of clinical aspects of Alzheimer's disease in a subject. Further provided are methods for diagnosing Alzheimer's disease, determining the progression or rate of memory decline of Alzheimer's disease, and predicting amyloid-tau status, brain amyloidosis status, and plasma p-tau217 status of a subject, using predictor value comparison to thresholds. Also provided are methods of selecting a subject for inclusion in a clinical trial, methods for treating the subject in need thereof, and kits providing the same.
Resumen de: WO2026155314A1
A dementia subtype diagnosis apparatus according to an embodiment of the present invention comprises: a data acquisition unit for collecting first protein data for effective protein candidates from a blood sample; a data processing unit for generating second protein data from the first protein data on the basis of an artificial intelligence analysis module, and generating combined protein data by combining the first protein data and the second protein data; and a diagnosis unit for determining a dementia subtype by using the combined protein data.
Resumen de: US20260210956A1
0000 Herein disclosed is configuring a layered receptor with at least one layer comprising graphene oxide and an biomarker binding layer configured to bind with a targeted biomarker, connecting a working electrode comprising carbon nanotubes (CNT) and a reference electrode to the layered receptor, and detecting events comprising the targeted biomarker binding layer with the biomarker binding layer, by measuring changes in impedance to a plurality of frequencies of an alternating current voltage signal applied through a patient's body fluid between the working electrode and the reference electrode. The layered receptor may further comprise a plurality of self-assembled layers, comprising, in sequence, a layer abutting the CNT and comprising a polymer and metal nanoparticles, a layer comprising an organosulfur, the graphene oxide layer and the biomarker binding layer. The biomarker binding layer may comprise Syn-211, LB509 or 5G4. The targeted biomarker may be alpha-synuclein. An implementation may report biomarker concentrations in real-time based on detected binding events.
Resumen de: WO2026154393A1
The present disclosure relates to use of GDF-15 as a novel biomarker for diagnosing, monitoring early-stage cancer, insulin resistance, and autoimmune diseases. Further, the present disclosure also relates to a multipurpose kit and personalized treatment across multiple health domains. Additionally, the present disclosure deals with an AI- driven personalized treatment and point of care (POC) platform using GDF-15 biomarker. There is a disclosure about dual biomarker system comprising GDF 15 and additional biomarker.
Resumen de: WO2026153996A1
The present disclosure provides methods of diagnosing and treating multiple sclerosis (MS) using an anti-CD3 antibody, and methods of monitoring progression of MS and/or treatment.
Resumen de: WO2026156063A1
Provided are methods for diagnosing and treating schizophrenia based on the presence of biomarkers for schizophrenia. The biomarkers can comprise specificity protein 4 (SP4) mRNA and heat shock protein 60 (HSP60) protein.
Resumen de: EP4779306A1
0001 The present invention relates to organoid co-cultures and their use in the investigation of diseases. The co-culture comprises at least one organoid, at least one stromal cell, and at least one immune cell. The presence or absence of the at least one change in the co-culture is determined e.g. in response to a proinflammatory stimulus.
Resumen de: CN108291916A
Provided are methods for the detection or quantization of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Abeta42) to amyloid beta 40 (Abeta40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
Resumen de: SE2530023A1
0001 Abstract This invention relates to analytical chemistry, and can be used in life sciences, including medicine. It provides a method for classifying a given complex sample into prespecified subgroups. The sample is composed of a mixture of compounds and it is analyzed by a technique with resolving power insufficient for separating individual compounds. As an example, the method can be used for assessing by blood sample analysis the risk of its donor for developing or fast progression of a neurological disease caused by protein aggregation. The invention is also suitable for assessing the quality of human blood plasma stored in blood storage facilities and suitability of that plasma for transfusion or further storage.
Resumen de: WO2024229161A1
The disclosure relates to compositions and methods for, inter alia, altering, e.g., enhancing, the level of GBA1 protein via delivery using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful, inter alia, in the treatment of subjects who have, have been diagnosed with, or are at risk of having a GBA1-related disorder, e.g., Parkinson's Disease (PD), Gaucher Disease (GD), Parkinson's Disease Dementia (PDD), Dementia with Lewy Bodies (DLB), or Lewy Body Dementia (LBD).
Resumen de: WO2025004009A1
The present technology comprises isolated endothelial progenitor cell (EPC) populations comprising PROCR+/- PDGFRA+/- EPCs and mesenchymal stem cell (MSC) populations, and methods of making and use thereof in treating hypoxic-ischemic encephalopathy (HIE) or brain injury in a subject.
Resumen de: WO2025120010A1
The invention relates to a nanopore-based sensing device. In one aspect of the invention, a nanopore-based sensing device comprises at least one membrane, wherein the membrane is arranged in a way that it separates two compartments within the device, both of which are accessible by an electrode, the membrane comprising at least one nanopore comprising pneumolysin (PLY) monomers.
Resumen de: CN122427282A
本发明公开了一种靶向Gal3的抗体及其应用。所述抗体包括轻链可变区和重链可变区，其中，所述重链可变区包含氨基酸序列分别如SEQ ID NO:6、SEQ ID NO:7和SEQ ID NO:8所示的HCDR1、HCDR2和HCDR3；和/或，所述轻链可变区包含氨基酸序列分别如SEQ ID NO:10、SEQ ID NO:11和SEQ ID NO:12所示的LCDR1、LCDR2和LCDR3。本发明提供的抗体能对抑制TGF‑β/Gal3诱导的小鼠胚胎成纤维细胞NIH3T3纤维化过程，可显著改善博莱霉素诱导的小鼠呼吸功能损伤，可有效恢复阿霉素、心肌梗死和糖尿病心肌病诱导的心衰小鼠的心脏收缩功能、逆转心室异常重构进程和逆转心脏病理组织改变。
Resumen de: CN122410031A
本发明提供了美金刚在制备预防和/或治疗表达GRIN2A的小细胞肺癌的药物中的应用，属于生物医药技术领域。本发明发现GluN2A蛋白是小细胞肺癌不良预后及靶向干预的重要分子标志物。另外，本发明发现美金刚、其衍生物或药用盐能够以剂量依赖的方式显著抑制小细胞肺癌细胞的活力、克隆形成能力、DNA复制活性及迁移能力，并有效破坏3D肿瘤球体的形成、诱导肿瘤细胞死亡，显著减小了小细胞肺癌异种移植瘤的体积和重量。本发明提供的伴随诊断与靶向用药策略，克服了传统非选择性用药的盲目性，为现有小细胞肺癌的治疗提供了新的药物解决方案。
Resumen de: WO2026153209A1
A biosensing element. The biosensing element comprises: a substrate, and a thin film transistor and a reaction chamber which are located on one side of the substrate. The thin film transistor comprises: a gate, a gate insulating layer, an active layer, a source and a drain which are stacked. The thin film transistor is located in the reaction chamber, and antibodies are provided in the reaction chamber. The thin film transistor further comprises a protective layer including at least one of a first protective layer and a second protective layer, wherein the first protective layer is located between the gate insulating layer and the active layer, the second protective layer comprises a first portion that is located on the side of the part of the active layer exposed by the source and the drain away from the substrate, and a water contact angle of a material of the protective layer is greater than that of a material of the gate insulating layer.
Resumen de: WO2025120152A1
The present invention relates to antibodies or binding fragments thereof for use in methods of identifying or diagnosing diseases associated with extracellular trap formation or release from cells, such as Neutrophil Extracellular Trap (NET)-associated pathologies or Eosinophil Extracellular Trap (EET) -associated pathologies.
Nº publicación: CN122422757A 17/07/2026
Solicitante:
奥科坦特公司
Resumen de: WO2025059015A1
Described herein is a system comprising a eukaryotic cell, wherein the eukaryotic cell comprises: a plasma membrane polypeptide coupled to a transcription factor by a linker, wherein the linker comprises a protease cleavable site; and a plasma membrane anchored protease; wherein the plasma membrane anchored protease is capable of cleaving the linker. The system can further include a reporter construct, wherein the transcription factor can bind to a promoter of the reporter construct to indicate an ability of the plasma membrane polypeptide to traffic to the plasma membrane.
BOPI
Sede Electrónica
